Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30034940 | 0.88 | LMNA (0.50) | LMNAMAPTHTTBLMAHR | |
| SCHEMBL3524411 | 0.88 | LMNA (0.50) | LMNAMAPTHTTBLMAHR | |
| SCHEMBL3519647 | 0.86 | MAPT (0.48) | LMNAMAPTHTTBLMAHR | |
| SCHEMBL155111 | 0.83 | MAPT (0.53) | LMNAMAPTHTTBLMAHR | |
| SCHEMBL29584634 | 0.83 | MAPT (0.53) | LMNAMAPTHTTBLMAHR | |
| SCHEMBL7839082 | 0.81 | MAPT (0.52) | LMNAMAPTHTTBLMAHR | |
| SCHEMBL6725684 | 0.79 | LMNA (0.41) | LMNAMAPTHTTBLMAHR | |
| SCHEMBL1669250 | 0.76 | CHRM2 (0.41) | MAPTCHRM2CHRM1CHRNB2CHRM3 | |
| SCHEMBL19141318 | 0.76 | CHRM2 (0.41) | MAPTCHRM2CHRM1CHRNB2CHRM3 | |
| SCHEMBL24384904 | 0.75 | PNMT (0.53) | LMNAMAPTHTTBLMAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122061-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| WO-2010041271-A2 | PROCESS FOR PREPARATION OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO[5,4-B]FURAN-8-YL)ETHYL] PROPIONAMIDE AND NOVEL INTERMEDIATES THEREOF | USV LIMITED (IN) | 2010-04-15 | — | — | WO | claimed |
| US-20020107391-A1 | Process for the synthesis of an endothelin receptor antagonist | FREY LISA F (US) | 2002-08-08 | — | — | US | claimed |
| WO-2026098493-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4720036-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2025-08-26 | — | — | US | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, NV (BE) | 2004-04-22 | — | — | US | disclosed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | disclosed |
| CN-1129602-C | 11-(substituted phenyl)-estra-4,9-diene derivatives | AKZO NOBEL NV (NL) | 2003-12-03 | — | — | CN | disclosed |
| US-20020107391-A1 | Process for the synthesis of an endothelin receptor antagonist | FREY LISA F (US) | 2002-08-08 | — | — | US | disclosed |
| US-6011025-A | HAVE ANTI-GLUCOCORTICOID ACTIVITY | AKZO NOBEL, N.V. (NL) | 2000-01-04 | — | — | US | disclosed |
| EP-0763541-B1 | 11-(Substituted phenyl)-estra-4,9-diene derivatives | AKZO NOBEL NV (NL) | 1999-07-28 | — | — | EP | disclosed |
| CN-1147520-A | 11-(substituted phenyl)-estra-4,9-diene derivatives | AKZO NOBEL NV (NL) | 1997-04-16 | — | — | CN | disclosed |
| EP-0763541-A1 | 11-(Substituted phenyl)-estra-4,9-diene derivatives | Akzo Nobel N.V. (NL) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | LMNA 1922/4885MAPT 1213/4885HTT 128/4885 |
| US-20250115581-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | CKS1B, CSNK1A1, CKS2 | LMNA 2078/4885MAPT 2308/4885HTT 4116/4885 |
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | APOL1, RNASE1, LOXL1 | LMNA 1246/4885MAPT 1838/4885HTT 2595/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | LMNA 876/4885MAPT 1/4885HTT 17/4885 |
| US-20040077684-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | LMNA 2298/4885MAPT 3115/4885HTT 3412/4885 |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | MRPL21, EMG1, RRS1 | LMNA 2517/4885MAPT 4422/4885HTT 3796/4885 |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | LMNA 3606/4885MAPT 3165/4885HTT 2704/4885 |
| US-20020107391-A1 | Process for the synthesis of an endothelin receptor antagonist | EDNRA, EDNRB, AGTR2 | LMNA 1487/4885MAPT 4506/4885HTT 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.